Vision by 2030

Responsibly lead the transition of adult smokers to a smoke-free future. 

Moving Beyond Smoking

Our industry stands at a pivotal moment. Today, approximately 22 million U.S. adult smokers are interested in less harmful tobacco products. That’s why we’re leveraging the resources across our companies, and through strategic investments, to offer the most diverse portfolio of products to satisfy adult preferences and transition adult smokers to smoke-free products.

Our team of more than 250 scientists, physicians, product developers, engineers and regulatory experts from around the world share a common goal – advancing tobacco harm reduction. To that end, we invest in the foundational science needed to demonstrate that smoke-free tobacco products are less harmful than cigarettes and to support the product applications we submit to the U.S. Food and Drug Administration (FDA).

Together, we are dedicated to researching innovative products, pursuing regulatory authorization by FDA and constructively engaging with regulatory bodies, the broader scientific community and other stakeholders.  Much of this work occurs at our Center for Research & Technology in Richmond, Virginia. 

Maria Gogova Photo at TSR

Dr. Maria Gogova Delivers Keynote Address at 2021 TSRC

Read our Chief Scientific Officer’s comments about "The Path Forward on Harm Reduction" delivered on August 30th at the Tobacco Science Research Conference.

Accompanying Slides

Peer-reviewed Image

Peer-reviewed publication in the journal Psychopharmacology

Learn more about Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes.